StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.63+0.23 (+16.43%)

Close on Nov 17, 2026Market cap $168.54MP/E –Yield –

Inovio Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Inovio Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $48.49M, down 22.1% year over year. For fiscal 2025 it was $54.21M, down 28.3% from the year before. Over ten years it grew -0.6% a year on average. The highest annual figure on record is $249.24M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.21M-28.3%
FY2024Dec 31, 2024$75.62M-12.8%
FY2023Dec 31, 2023$86.68M-53.8%
FY2022Dec 31, 2022$187.65M-24.7%
FY2021Dec 31, 2021$249.24M+164.5%
FY2020Dec 31, 2020$94.25M+7.1%
FY2019Dec 31, 2019$88.02M-7.6%
FY2018Dec 31, 2018$95.26M-3.4%
FY2017Dec 31, 2017$98.57M+11.1%
FY2016Dec 31, 2016$88.71M+53.5%
FY2015Dec 31, 2015$57.79M+69.5%
FY2014Dec 31, 2014$34.10M+59.6%
FY2013Dec 31, 2013$21.37M+18.8%
FY2012Dec 31, 2012$17.98M-10.2%
FY2011Dec 31, 2011$20.03M+51.1%
FY2010Dec 31, 2010$13.26M+40.9%
FY2009Dec 31, 2009$9.41M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.83M-25.4%
Q1 FY2026Mar 31, 2026$14.07M-12.6%
Q4 FY2025Dec 31, 2025$10.26M-20.4%
Q3 FY2025Sep 30, 2025$13.33M-28.8%
Q2 FY2025Jun 30, 2025$14.52M-37.1%
Q1 FY2025Mar 31, 2025$16.09M-23.1%
Q4 FY2024Dec 31, 2024$12.89M-25.3%
Q3 FY2024Sep 30, 2024$18.73M+20.8%
Q2 FY2024Jun 30, 2024$23.09M-2.8%
Q1 FY2024Mar 31, 2024$20.91M-30.7%
Q4 FY2023Dec 31, 2023$17.25M-59.0%
Q3 FY2023Sep 30, 2023$15.50M-53.1%
Q2 FY2023Jun 30, 2023$23.74M-57.9%
Q1 FY2023Mar 31, 2023$30.18M-46.1%
Q4 FY2022Dec 31, 2022$42.12M-54.4%
Q3 FY2022Sep 30, 2022$33.09M-29.7%
Q2 FY2022Jun 30, 2022$56.46M-20.3%
Q1 FY2022Mar 31, 2022$55.98M+43.4%
Q4 FY2021Dec 31, 2021$92.30M+250.9%
Q3 FY2021Sep 30, 2021$47.09M+78.0%
Q2 FY2021Jun 30, 2021$70.81M+216.4%
Q1 FY2021Mar 31, 2021$39.04M+104.3%
Q4 FY2020Dec 31, 2020$26.30M+19.5%
Q3 FY2020Sep 30, 2020$26.46M+38.2%
Q2 FY2020Jun 30, 2020$22.38M-0.5%
Q1 FY2020Mar 31, 2020$19.11M-21.6%
Q4 FY2019Dec 31, 2019$22.00M-16.5%
Q3 FY2019Sep 30, 2019$19.14M-12.4%
Q2 FY2019Jun 30, 2019$22.49M+0.1%
Q1 FY2019Mar 31, 2019$24.39M-0.8%
Q4 FY2018Dec 31, 2018$26.37M+7.0%
Q3 FY2018Sep 30, 2018$21.85M-14.3%
Q2 FY2018Jun 30, 2018$22.46M-5.9%
Q1 FY2018Mar 31, 2018$24.58M+0.1%
Q4 FY2017Dec 31, 2017$24.64M+3.1%
Q3 FY2017Sep 30, 2017$25.51M-5.4%
Q2 FY2017Jun 30, 2017$23.88M–
Q1 FY2017Mar 31, 2017$24.54M–
Q4 FY2016Dec 31, 2016$23.91M–
Q3 FY2016Sep 30, 2016$26.98M–

More Inovio Pharmaceuticals figures

See a number that looks wrong?